patient history News
-
World Thrombosis Day
On World Thrombosis Day, October 13, 2021, Emosis is proud to be a "messenger" of the "Eyes open to Thrombosis" information campaign. Eyes open to Thrombosis WTD is an educational campaign to raise awareness and educate the public to the importance of reducing death and disability from thrombosis. It is a global alliance of thousands of local, regional, national and international ...
-
03/06/2017
CALGARY, AB / ACCESSWIRE / April 6, 2017 / Imaging Dynamics Company Ltd. ("IDC" or the "Company") (TSXV: IDL) reports its financial results for the December 31, 2016 fiscal year-end. 2016 Summary: Gross revenues for the three and twelve months ended December 31, 2016 were $4,351,943 and $7,543,199, compared to $458,448 and $2,435,667 respectively in the same periods of 2015. Gross ...
-
Medical Diagnostic Kit
There is a huge gap between the state of the art of health care, which is available in urban areas and developed countries, and the kind of healthcare services available to the rural population in developing countries. Many people in poorer societies suffer because of unavailability of simple and standard medical facilities and diagnostics. Neurosynaptic Communications plans to bridge this gap ...
-
IDC Receives FDA Approval for Innovative DR Imaging Devices
CALGARY, AB / ACCESSWIRE / February 22, 2017 / Imaging Dynamics Company Ltd. ("IDC" or the "Company") (TSX-V: IDL) is pleased to announce that it received notification today that the United States Food and Drug Administration ("FDA") has granted Market Clearance (510k) approval for its new Digital Radiography ("DR") product line - Aquarius 8600 1717TC and Aquarius 8600 1417TC. These products ...
-
Bluegrass Vascular Announces New Paper Reporting Ability to Eliminate Use of a Femoral Catheter with the Surfacer System
Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of a case report demonstrating the ability to utilize the Surfacer® System to perform the Inside-Out® procedure and obtain right-sided central venous access in a patient with central venous occlusion and ...
-
New Blood Test Helps Clinicians Pinpoint A Potentially Life-Threatening Sensitization to Insect Stings
ImmunoCAP Specific IgE Stinging Insect Allergen Components have been cleared by the U.S. Food & Drug Administration (FDA) for in vitro diagnostic use. Results from these component tests can act as a diagnostic aid to help specialists and other healthcare providers discriminate between true sensitization and cross reactivity, identify culprit insect(s) in patients with inconclusive patient ...
-
Lupin Signs Promotional Agreement with Exeltis on SOLOSEC® expanding access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis
Lupin Pharmaceuticals Inc., (Lupin) and Exeltis USA Inc. announced a promotional agreement for Exeltis to promote SOLOSEC along with Exeltis’ existing line of Women’s Health products, further enhancing value to OBGYNs and their patients. SOLOSEC is indicated for the treatment of Bacterial Vaginosis in adult women (a common vaginal infection) and Trichomoniasis in adults (the most ...
-
FDA has granted the company a Breakthrough Device Designation for its MIScoli™ system
Spino Modulation Inc., a subsidiary of Spinologics Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted the company a Breakthrough Device Designation for its MIScoli™ system, an innovative vertebral body tethering (VBT) device to treat scoliosis in young adolescents. The FDA Breakthrough Device Program is intended to help patients receive more timely access to ...
-
ViciniVax announces first patient treated in Phase I study with immunotherapy Vvax001 for HPV-related precancers and cancer
Groningen, the Netherlands - 3 February 2017 - ViciniVax, a Dutch biopharmaceutical company in Groningen, announced today the treatment of the first patient with Vvax001 in a Phase I study in patients with a history of cervical intraepithelial neoplasia (CIN) 2 and 3 or cervical cancer. The Phase I study is an investigator-initiated Phase I clinical trial conducted by the Department of Obstetrics ...
By ViciniVax BV
-
Maryland Scientists Identify High Rates of Dangerous Bacteria Growth in Infected Patient Rooms
Scientists from the University of Maryland’s School of Medicine recently conducted research into the presence of multi-drug resistant Acinetobacter baumannii (MDR-AB) in patient rooms in medical facilities. The research was published in the American Journal of Infection Control (AJIC). Researchers found that MDR-AB was present in the environment of 48% of the rooms of patients infected ...
-
XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease
XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report a significant potential market opportunity for its oral dissolvable (“ODF”) biosensor screening tests for oral inflammation. Certain buprenorphine medicines prescribed to treat opioid use disorder (“OUD”) and pain have been recently associated ...
-
Meet the Molds - Important aeroallergens in allergy testing
Despite being defined more than 100 years ago; atmospheric molds have remained undervalued as an important aeroallergen in allergy testing. Of the estimated number of more than 1 million different fungal species, approximately 80 species have been linked with respiratory allergy. However, epidemiologic studies have suggested that the prevalence of allergies to molds is less than 3% in an allergic ...
-
NIH Statement on World Asthma Day 2015
On World Asthma Day 2015, the National Institutes of Health stands with the international community to renew our commitment to advance our understanding of asthma and develop effective strategies to manage and prevent the disease. Within a broad asthma research portfolio, NIH-supported scientists are making progress in understanding how certain exposures—such as to microbes, ...
-
Transcript: CDC Update on COVID-19
OPERATOR: AT THIS TIME, ALL PARTICIPANTS ARE ON LISTEN-ONLY MODE. SO, IF YOU WOULD LIKE TO ASK A QUESTION, PLEASE PRESS STAR AND THEN ONE. TODAY’S CONFERENCE IS BEING RECORDED. IF YOU HAVE ANY OBJECTIONS, YOU MAY DISCONNECT AT THIS TIME. AND NOW I WOULD LIKE TO TURN THE MEETING OVER TO MR. BENJAMIN HAYNES. SIR YOU MAY BEGIN. HAYNES: THANK YOU, BRITTANY. AND THANKS TO EVERYONE ...
-
Dr. John Peabody Delivers 2021 Rocky Vista University (RVU) Commencement Speech
Rocky Vista University (RVU) celebrated the graduation of 154 medical students from its College of Osteopathic Medicine (COM) and 37 graduate students from its Master of Science in Biomedical Sciences (MSBS) program on the Colorado campus. RVU hosted the small-scale commencement ceremony for students and their guests in the University’s auditoriums with masks and distanced ...
-
Bexson Biomedical Hires Veteran Medical Device Development Leader, Will Focus On New Dosing & Delivery Solutions For Controlled Substances
Bexson Biomedical, Inc., a research-stage company developing dosing and delivery solutions for mental health and pain management indications, announced today the addition of medical device and combination product developer, Sheldon Moberg, to its senior leadership team. As Senior VP, Drug Delivery, Moberg will lead the development of Bexson's drug delivery technologies, starting with a wearable ...
-
Berlin Heart Received CE Mark and Announces First Implantation of the Latest Cannula Generation to Treat Heart Patients Waiting for a Donor Heart
Berlin, September 2021: Berlin Heart today announces the CE mark and first implantation of an innovative outflow cannula for mechanical circulatory support with the paracorporeal pulsatile EXCOR® ventricular assist device. The EXCOR® Graft Cannula* connects the outflow side of the blood pump to the ascending aorta for left ventricular support or to the pulmonary artery for right ...
-
Bluegrass Vascular Announces Publication Reporting Experience with Cardiac Resynchronization Therapy Device Lead Placement following Use of Surfacer System
Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, announced today the publication of a report documenting the clinical utility of the Surfacer System to gain venous access prior to the placement of cardiac resynchronization therapy (CRT) device leads in a patient with obstructed central veins. ...
-
xCures and Novocure partner to better understand quality of life in glioblastoma
xCures, Inc., is proud to announce their partnership with Novocure with the intent to develop the first comprehensive, longitudinal Quality of Life (QoL) dataset for glioblastoma (GBM) patients. The alliance between both oncology companies will leverage xCures’ novel, patient-centric platform and deep connections to GBM patient and provider communities through direct engagement with GBM ...
By xCures
-
Agilent Technologies to Collaborate with University of Queensland on Oral Cancer Research
Agilent Technologies Inc. (NYSE: A) today announced it will collaborate with the University of Queensland Centre for Clinical Research in Brisbane, Australia, to increase understanding of the genomic differences between young and older patients with oral cancer and between progressive and non-progressive oral potentially malignant lesions. Oral cancer is part of a group of cancers commonly ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you